FDA
-
-
-
-
-
-
-
Creative Medical gets patent allowance for exosome-based T1D therapy
-
-
-
-
-
-
-
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapie
-
-
-
-
-
-
-
Creative Medical Technology shares shareholder letter on clinical progress
-
-
-
-
-
-
-
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using Al
-
-
-
-
-
-
-
Creative Medical Technology Holdings (CELZ) Issues Corporate Update
-
-
-
-
-
-
-
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
-
-
-
-
-
-
-
What Is Allogeneic Cell Therapy, And What’s Driving This Market’s 25%+ Annual Global Growth?
-
335,944 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


